S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
TSE:ONC

Oncolytics Biotech (ONC) Stock Price, News & Analysis

C$1.45
+0.07 (+5.07%)
(As of 03/28/2024 ET)
Today's Range
C$1.39
C$1.45
50-Day Range
C$1.21
C$1.70
52-Week Range
C$1.20
C$4.49
Volume
83,473 shs
Average Volume
75,475 shs
Market Capitalization
C$109.36 million
P/E Ratio
N/A
Dividend Yield
0.31%
Price Target
C$9.00

Oncolytics Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
520.7% Upside
C$9.00 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.45 out of 5 stars

ONC stock logo

About Oncolytics Biotech Stock (TSE:ONC)

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONC Stock Price History

ONC Stock News Headlines

Closing Bell: Oncolytics Bio down on Friday (ONC)
Futures Retreat Sharply
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
A Preview Of Oncolytics Biotech's Earnings
Oncolytics Biotech Inc ONC
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)
Oncolytics Biotech's Earnings Outlook
Stocks in play: Oncolytics Biotech, Inc.
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$9.00
High Stock Price Target
C$9.00
Low Stock Price Target
C$9.00
Potential Upside/Downside
+520.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
C$-27,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.34 per share
Book Value
C$0.37 per share

Miscellaneous

Free Float
N/A
Market Cap
C$109.36 million
Optionable
Not Optionable
Beta
1.49
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., President, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., Vice President of Product Development
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen F.C.A.
    FCA, LLD, Consultant

ONC Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONC shares.
View ONC analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price target for 2024?

2 analysts have issued 1 year price objectives for Oncolytics Biotech's shares. Their ONC share price targets range from C$9.00 to C$9.00. On average, they anticipate the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 520.7% from the stock's current price.
View analysts price targets for ONC
or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2024?

Oncolytics Biotech's stock was trading at C$1.79 at the beginning of 2024. Since then, ONC stock has decreased by 19.0% and is now trading at C$1.45.
View the best growth stocks for 2024 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ONC earnings forecast
.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ONC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners